The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
Three-year CSR partnership to scale community-led mental healthcare access across Chhindwara district
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Subscribe To Our Newsletter & Stay Updated